Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: Invest New Drugs. 2021 Mar 1;39(4):1072–1080. doi: 10.1007/s10637-021-01090-w

Table 3.

Safety, AEs at least possibly related (N=18)

Any Grade Grade 1 or 2 Grade 3 or higher
Fatigue 11 (61.1) 11 (61.1)
Nausea/vomiting 7 (38.9) 7 (38.9)
Hypertension 7 (38.9) 6 (33.3) 1 (5.6)
Hand-foot syndrome 7 (38.9) 5 (27.8) 2 (11.1)
Weight loss 5 (27.8) 5 (27.8)
Diarrhea 4 (22.2) 4 (22.2)
Rash 4 (22.2) 3 (16.7) 1 (5.6)
Oral Mucositis 4 (22.2) 2 (11.1) 2 (11.1)
AE; adverse events